Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline, and deep institutional backing. VIR's lead CHD drugs, Tobevibart and Elebsiran, target a large, underserved market with potential for high margins and accelerated regulatory approval. The Astellas partnership secures funding for oncology development, extends the cash runway into 2028, and minimizes dilution risk ahead of key catalysts.
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at higher doses, with Astellas providing $335M upfront and up to $1.37B in milestones. Recent licensing deals and a strong cash position ($781.6M) help offset 2025 net loss of $(438M), while pipeline advances target HDV and multiple oncology indications.
What's Happening With VIR Stock?
Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging Phase 1 results. This information, combined with an impressive revenue exceedance, is fostering considerable optimistic sentiment.
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.76 per share a year ago.
Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript
Vir Biotechnology, Inc. ( VIR ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jason O'Byrne - Executive VP & CFO Marianne De Backer - CEO & Director Mark Eisner - Executive VP & Chief Medical Officer Conference Call Participants Kun Wang - Barclays Bank PLC, Research Division Rohit Bhasin - Morgan Stanley, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Mario Joshua Chazaro Cortes - Evercore ISI Institutional Equities, Research Division Ellen Horste - TD Cowen, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Joseph Stringer - Needham & Company, LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, and welcome to Vir Biotechnology's Third Quarter 2025 Financial Results and Corporate Update Call.
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $1.56 per share a year ago.
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
Vir Biotechnology (VIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Jason O'Byrne - Executive VP & CFO Marianne De Backer - CEO & Director Mark D. Eisner - Executive VP & Chief Medical Officer Mika Kakefuda Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Avraham Leib Novick - Morgan Stanley, Research Division Huidong Wang - Barclays Bank PLC, Research Division Joseph Robert Stringer - Needham & Company, LLC, Research Division Mazahir Lukman Alimohamed - Leerink Partners LLC, Research Division Patrick Ralph Trucchio - H.C.
